Completed PHASE1 INTERVENTIONAL 1-arm NCT02261532

A Phase I Study of TAS-102 in Solid Tumors

A Phase 1, OPEN-Label, Non-randomized, Pharmacokinetic Study of TAS-102 in Chinese Patients With Solid Tumors

Sponsor: Taiho Pharmaceutical Co., Ltd.

Conditions Advanced or Metastatic Solid Tumors

Interventions TAS-102

Updated 8 times since 2017 Last updated: Oct 29, 2024 Started: Sep 30, 2014 Primary completion: Oct 31, 2015 Completion: Jun 30, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Advanced or Metastatic Solid Tumors and is currently completed. Taiho Pharmaceutical Co., Ltd. leads this study, which shows 8 recorded versions since 2014 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

Dec 2024 — Present [monthly]

Completed PHASE1
Nov 2024 — Dec 2024 [monthly]

Completed PHASE1
Sep 2024 — Nov 2024 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Aug 2017 — Jun 2018 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Jan 2017 — Aug 2017 [monthly]

Active Not Recruiting PHASE1

First recorded

Sep 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Taiho Pharmaceutical Co., Ltd.

Data source: Taiho Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China